Campus Moncloa

Publicaciones científicas

Publicaciones vinculadas con el clúster

2023

• Thienopyrimidine derivatives as GPR55 receptor antagonists: Insight into structure-activity relationship. Figuerola-Asencio L, Morales P, Zhao P, Hurst D, Sayed S, Colón K, Gómez-Cañas M, Fernández-Ruiz J, Croatt M, Reggio P, Abood M, Jagerovic N. ACS Med Chem Lett. 2022 Dec 2;14(1):18-25; eCollection 2023 Jan 12
  Categoría: Chemistry, Medicinal       Cuartil: 2º
  Factor de impacto: 4.632        
• Retinal tissue shows glial changes in Dravet Symdrome knock-in mouse model. Salazar JJ, Satriano A, Matamoros JA, Fernández-Albarral JA, Salobrar-García E, López-Cuenca I, de Hoz R, Sánchez-Puebla L, Ramírez JM, Alonso C, Satta V, Hernández-Fisac I, Sagredo O, Ramírez AI. Int J Mol Sci. 2023 Feb 1;24(3):2727.
  Categoría: Biochemistry & Molecular Biology       Cuartil: 1º
  Factor de impacto: 6.208        
• Preclinical investigation in FAAH inhibition as a neuroprotective therapy for frontotemporal dementia using TDP-43 transgenic male mice. Santos-García I, Rodríguez-Cueto C, Villegas P, Piscitelli F, Lauritano A, Shen C, di Marzo V, Fernández-Ruiz J, de Lago E. J Neuroinflammation. 2023 May 6;20(1):108
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 9.594        
• Disease-modifying effects of cannabidiol, β-caryophyllene and their combination in Syn1-Cre/Scn1aWT/A1783V mice, a preclinical model of Dravet síndrome. Alonso C, Satta V, Hernández-Fisac I, Fernández-Ruiz J, Sagredo O. Neuropharmacology. 2023 Jun 6;109602
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 5.273        
• The cannabigerol derivative VCE-003.2 exerts therapeutic effects in 6-Hydroxydopamine-lesioned mice: Comparison with the classic dopaminergic replacement therapy. Rodríguez-Carreiro S, Navarro E, Muñoz E, Fernández-Ruiz J. Brain Sci. 2023 Aug 31;13(9):1272
  Categoría: Neurosciences       Cuartil: 3º
  Factor de impacto: 3.300        

2022

• New statement about NRF2 in amyotrophic lateral sclerosis and frontotemporal dementia. Lastres-Becker I, de Lago E, Martínez A, Fernández-Ruiz J. Biomolecules. 2022 Aug 29;12(9):1200
  Categoría: Biochemistry & Molecular Biology       Cuartil: 2º
  Factor de impacto: 6.064        
• Discovery of Mitophagy Inhibitors with Therapeutic Potential in Different Familial Amyotrophic Lateral Sclerosis Mutations. Ines Maestro, Laura R de la Ballina, Gracia Porras, Silvia Corrochano, Eva De Lago, Anne Simonsen, Patricia Boya, Ana Martinez. Int J Mol Sci. 2022 Oct 21;23(20):12676
  Categoría: Biochemistry & Molecular Biology       Cuartil: 1º
  Factor de impacto: 6.208        
• Preclinical investigation of beta-caryophyllene as a therapeutic agent in a experimental murine model of Dravet síndrome. Alonso C, Satta V, Díez P, Fernández-Ruiz J, Sagredo O. Neuropharmacology, 205.108914.
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 5.250        
• TDP-43 Modulation by Tau-Tubulin Kinase 1 Inhibitors: A New Avenue for Future Amyotrophic Lateral Sclerosis Therapy. Nozal V, Martinez-Gonzalez L, Gomez-Almeria M, Gonzalo-Consuegra C, Santana P, Chaikuad A. Perez-Cuevas E, Knapp S, Lietha D, Ramirez D, Petralla S, Monti B, Gil C, Martin-Requero A. Palomo V, de Lago E, Martínez A. J Med Chem . 2022 Jan 27;65(2):1585-1607
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 7.446        

2021

• Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson’s disease using 6-hydroxydopamine-lesioned mice. Burgaz S, García MC, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, Fernández-Ruiz J. Mol Cell Neurosci. 2021 Jan;110:103583
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 3.182        
• Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. Rojas-Prats E, Martínez-González L, Gonzalo-Consuegra C, Liachko NF, Pérez C, Ramírez D, Kraemer BC, Martín-Requero A, Pérez DI, Gil C, de Lago E, Martínez A. Eur J Med Chem. 2021 Jan 15;210:112968
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 5.572        
• Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer´s disease. Sánchez-Montero JM, Agis-Torres A, Solano D, Söllhuber M, Fernández M, Villaro W, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Egea J, Martín MI, Girón R Eur J Pharmacol . 2021 Jan 15;895:173875
  Categoría: Pharmacology & Pharmacy       Cuartil: 2º
  Factor de impacto: 3.263        
• Neuropathological characterization of a Dravet sÍndrome knock-in mouse model useful for investigating cannabinoid treatments. Satta V, Alonso C, Díez P, Martín-Suárez S, Rubio M, Encinas JM, Fernández-Ruiz J, Sagredo O. Frontiers in Molecular Neuroscience, 13 602801 (2020)
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 4.057        
• Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis. Rodríguez-Cueto C, García-Toscano L, Santos-García L, Gómez-Almería M, Gonzalo-Consuegra C, Espejo-Porras F, Fernández-Ruiz J, de Lago E. Br J Pharmacol . 2021 Mar;178(6):1373-1387. Epub 2021 Feb 20.
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 7.730        
• Retinal ganglion cell loss and microglial activation in a SOD1G93A mouse model of amiyotrophic lateral sclesoris. Rojas P, Ramírez AI, Cadena M, Fernández-Albarral JA, Salobrar-García E, López-Cuenca I, Santos-García I, de Lago E, Urcelay-Segura JL, Ramírez JM, de Hoz R, Salazar JJ. International Journal of Molecular Sciences. 2021 Feb 7;22(4):1663.
  Categoría: Biochemistry & Molecular Biology       Cuartil: 1º
  Factor de impacto: 4.556        
• Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration. Galán-Ganga, M, Rodríguez-Cueto C, Merchán-Rubira J, Hernández F, Ávila J, Posada-Ayala M, Lanciego JL, Luengo E, López MG, Rábano A, Fernández-Ruiz J, Lastres-Becker I. Acta Neuropathol Commun. 2021 May 17;9(1):90.
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 6.270        
• (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice. González-Mariscal I, Carmona-Hidalgo B, Winkler M, Unciti-Broceta JD, Escamilla A, Gómez-Cañas M, Fernández-Ruiz J, Fiebich BL, Romero-Zerbo SY, Bermúdez-Silva FJ, Collado JA, Muñoz E. Pharmacological Research 169, July 2021, 105492
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 5.893        
• Neuroprotection with the cannabidiol quinone derivative VCE-004.8 (EHP-101) against 6-hydroxydopamine in cell and murine models of Parkinson’s disease. Burgaz S, García MC, Gómez-Cañas M, Rolland A, Muñoz E, Fernández-Ruiz J. Molecules . 2021 May 28;26(11):3245.
  Categoría: Biochemistry & Molecular Biology       Cuartil: 2º
  Factor de impacto: 3.267        
• Tideglusib, a non-ATP competitive inhibitor of GSK-3β as a drug candidate for the treatment of Amyotrophic Lateral Sclerosis. Martinez-Gonzalez L, Gonzalo-Consuegra C, Gómez-Almería M, Porras G, de Lago E, Martin-Requero A, Martinez A. Int J Mol Sci. 22(16):8975
  Categoría: Biochemistry & Molecular Biology       Cuartil: 1º
  Factor de impacto: 5.923        
• Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice, a model of amyotrophic lateral sclerosis. Rodríguez-Cueto C, Gómez-Almería M, García-Toscano L, Romero J, Hillard CJ, de Lago E, Fernández-Ruiz J. Brain Pathol. 2021 May 13;e12972. Online ahead of print.
  Categoría: Pathology       Cuartil: 1º
  Factor de impacto: 5.568        
• BiP heterozigosity aggravates pathological deterioration in experimental amyotrophic lateral sclerosis: possible relation with CB1 receptor-mediated neuroprotection? Gómez-Almería M, Burgaz S, Costas-Insua C, Rodríguez-Cueto C, Santos-García i, Eodriguez-Crespo i, García MC, Guzmán M, de Lago E, Fernández-Ruiz J. Int J Mol Sci. 2021 Nov 20;22(22):12533
  Categoría: Biochemistry & Molecular Biology       Cuartil: 1º
  Factor de impacto: 5.923        
• Preclinical investigation in neuroprotective effects of the GPR55 ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis. Burgaz S, García MC, Gonzalo-Consuegra C, Gómez-Almería M, Ruiz-Pino F, Unciti JD, Gómez-Cañas M, Alcalde J, Morales P, Jagerovic N, Rodríguez-Cueto C, de Lago E, Muñoz E, Fernández-Ruiz J. Molecules . 2021 Dec 16;26(24):7643
  Categoría: Biochemistry & Molecular Biology       Cuartil: 2º
  Factor de impacto: 4.411        

2020

• Pharmacokinetics of Sativex in dogs: Towards a potential cannabinoid-based therapy for canine disorders. Fernández-Trapero M, Pérez-Díaz C, Espejo-Porras F, de Lago E, Fernández-Ruiz J. Biomolecules. 2020 Feb 11;10(2). pii: E279
  Categoría: Biochemistry & Molecular Biology       Cuartil: 1º
  Factor de impacto: 4.694        
• Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment. Martínez-González L, Rodríguez-Cueto C, Cabezudo D, Bartolomé F, Andrés-Benito P, Ferrer I, Gil C, Martín-Reguero A, Fernández-Ruiz J, Martínez A, de Lago E. Sci Rep . 2020 Mar 10;10(1):4449.
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 4.011        
• Beneficial effects of the phytocannabinoid Delta9-THCV in L-DOPA-induced dyskinesia in Parkinson´s disease. Espadas I, Keifman E, Palomo-Garo C, Burgaz S, García MC, Fernández-Ruiz J, Moratalla R. Neurobiol Dis. 2020 Jul;141:10489
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 5.160        
• Possible therapeutic applications of cannabis in the neuropsychopharmacology field. Fernández-Ruiz J, Galve-Roperh I, Sagredo O, Guzmán M. Eur Neuropsychopharmacol. 2020 Jul;36:217-234
  Categoría: Clinical Neurology       Cuartil: 1º
  Factor de impacto: 4.468        
• Discovery of homobivalent bitopic ligands of the cannabinoid CB2 receptor. Morales P, Navarro G, Gómez-Autet M, Redondo L, Fernández-Ruiz J, Pérez-Benito L, Cordomi A, Pardo L, Franco R, Jagerovic N. Chemistry a European Journal. 2020 Dec 4;26(68):15839-15842
  Categoría: Chemistry, Organic       Cuartil: 1º
  Factor de impacto: 4.857        
• Δ9-Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: role of PPARγ and CB1 receptors. Palomares B, Garrrido-Rodríguez M, Gonzalo-Consuegra C, Gómez-Cañas M, Saenoon S, Soliva R, Collado J, Fernández-Ruiz J, Morello G, Calzado M, Appendino G, Muñoz E. Br J Pharmacol. 2020 Jun 8;177(17):4034-4054
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 7.730        

2019

• Cannabidiol administration prevents hypoxia-ischemia-induced hypomyelination in newborn rats. Ceprián M, Vargas C, García-Toscano L, Penna F, Jiménez-Sánchez L, Achicallende S, Elezgarai I, Grandes P, Hind W, Pazos MR, Martínez-Orgado J. Front Pharmacol. 2019 Sep 26;10:1131. eCollection 2019.
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 3.720        
• Structure-effect relationships of novel semi-synthetic cannabinoid derivates. Götz MR, Collado JA, Fernández-Ruiz J, Fiebich BL, García-Toscano L, Gómez-Cañas M, Koch O, Leha A, Muñoz E, Navarrete C, Pazos MR, Holgrabe U. Front Pharmacol. 2019 Nov 20;10:1284. eCollection 2019
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 3.845        
• The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. Fernández-Ruiz, J. British Journal of Pharmacology, 176 1370-1383
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 6.810        
• Targeting glial CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. Espejo-Porras F, García-Toscano L, Rodríguez-Cueto C, Santos-García I, de Lago E, Fernández-Ruiz J. British Journal of Pharmacology 176, 1585-1600
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 6.810        
• Endocannabinoid system in spinocerebellar ataxia type-3 and other autosomal-dominant cerebellar ataxias: potential role in pathogenesis and expected relevance as neuroprotective targets. Gómez-Ruiz M, Rodríguez-Cueto C, Luna-Piñel E, Hernández ML, Fernández-Ruiz J. Front Mol Neurosci. 2019 Apr 24;12:94
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 3.902        
• Morphine self-administration, Lewis rats, mTOR pathway, extinction, protein synthesis. Ucha M, Coria S, Núñez-Carranza A, Santos-Toscano R, Roura-Martínez D, Fernández-Ruiz J, Higuera-Matas A, Ambrosio E. J Psychopharmacol. 2019 Jul;33(7):882-893. doi: 10.1177/0269881119836206. Epub 2019 Mar 19.
  Categoría: Clinical Neurology       Cuartil: 1º
  Factor de impacto: 4.738        
• Development of an oral treatment with the PPAR--acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson´s disease. Burgaz S, García MC, Gómez-Cañas M, Muñoz E, Fernández-Ruiz J. Molecules. 2019 Jul 25;24(15). pii: E2702.
  Categoría: Biochemistry & Molecular Biology       Cuartil: 2º
  Factor de impacto: 3.060        

2018

• Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists. Murineddu G, Deligia F, Ragusa G, García-Toscano L, Gómez-Cañas M, Asproni B, Satta V, Cichero E, Pazos MR, Fossa P, Loriga G, Fernández-Ruiz J, Pinna GA. Bioorg Med Chem. 2018 Jan 1;26(1):295-307
  Categoría: Chemistry, Organic       Cuartil: 2º
  Factor de impacto: 2.930        
• Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor. García MC, Gómez-Cañas M, Burgaz S, Palomares B, Gómez-Gálvez Y, Palomo C, Campo S, Ferrer-Hernández J, Pavicic C, Navarrete C, Bellido ML, García-Arencibia M, Pazos MR, Muñoz E, Fernández-Ruiz J. J Neuroinflammation. 2018 Jan 16;15(1):19.
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 7.946        
• Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients. Espejo-Porras F, Fernández-Ruiz J, de Lago E. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Jan 19:377-386.
  Categoría: Clinical Neurology       Cuartil: 2º
  Factor de impacto: 3.054        
• VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and inflammation trough PPAR-and CB2-dependent pathways. Del Río C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Bellido ML, Ortega R, Pérez-Sánchez C, López-Pedrera C, Appendino G, Calzado M, Muñoz E. Br J Pharmacol. 2018 Oct;175(19):3813-3831
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 6.810        
• Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis. Rodríguez-Cueto C, Santos-García I, García-Toscano L, Espejo-Porras F, Bellido ML Fernández-Ruiz J, Muñoz E, de Lago E. Biochem Pharmacol. 2018 Nov;157:217-226
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.235        
• Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J. Biochem Pharmacol. 2018 Nov;157:67-84.
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.235        
• Cannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders. Sagredo O, Palazuelos J, Gutierrez-Rodriguez A, Satta V, Galve-Roperh I, Martínez-Orgado J. Biochem Pharmacol. 2018 Nov;157:85-96
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.235        

2017

• Synthesis of a novel CB2 cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione. Morales P, Moreno L, Fernández-Ruiz J, Jagerovic N. J. Porphyrins Phthalocyanines 2017; 21: 67–76
  Categoría: Chemistry, Multidisciplinary       Cuartil: 3º
  Factor de impacto: 1.087        
• Effects of a Sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of Huntington’s disease. Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz Int J Mol Sci. 2017 Mar 23;18(4). pii: E684
  Categoría: Biochemistry & Molecular Biology       Cuartil: 2º
  Factor de impacto: 3.257        
• Altered striatal endocannabinoid signalling in a transgenic mouse model of spinocerebellar ataxia type-3. Rodríguez-Cueto C, Hernández ML, Hillard C, Maciel P, Valdeolivas S, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. PLoS One. 2017 Apr 27;12(4):e0176521.
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 3.057        
• Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Fernández-Trapero M, Espejo-Porras F, Rodríguez-Cueto C, Coates J, Pérez-Diaz C, de Lago E, Fernández-Ruiz J. Dis Model Mech. 2017 May 1;10(5):551-558.
  Categoría: Pathology       Cuartil: 1º
  Factor de impacto: 4.316        
• Modeling neurodegenerative disorders for developing cannabinoid-based neuroprotective therapies. Fernández-Ruiz J, Gómez-Ruiz M, García MC, Hernández M, Ramos JA. Methods Enzymol. 2017;593:175-198
  Categoría: Biochemical Research Methods       Cuartil: 3º
  Factor de impacto: 2.088        
• New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. Ragusa G, Gómez-Cañas M, Morales P, Rodríguez-Cueto C, Pazos MR, Asproni B, Cichero E, Fossa P, Pinna GA, Jagerovic N, Fernández-Ruiz J, Murineddu G. Eur J Med Chem. 2017 Jan 4;127:398-412.
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 3.902        

2016

• Deiana V, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Asproni B, Cichero E, Fossa P, Muñoz E, Deligia F, Murineddu G, García-Arencibia M, Pinna GA. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties. Eur J Med Chem. 2016 Feb 6;112:66-80
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 5.447        
• Del Río C, Navarrete C, Collado JA, Bellido M, Gomez-Cañas M, Pazos MR, Fernandez-Ruiz J, Pollastro F, Appendino G, Calzado MA, Cantarero I, Muñoz E. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways. Sci Rep. 2016 Feb 18;6:21703
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 5.578        
• Morales P, Whyte L, Chicharro R, Gómez-Cañas M, Pazos MR, Goya P, Irving AJ, Fernández-Ruiz J, Ross RA, Jagerovic N. Identification of novel GPR55 modulators using cell-impedance-based label-free technology. Journal of Medicinal Chemitry, 2016 Mar 10;59(5):1840-53
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 5.447        
• García MC, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol. 2016 Jul;173(13):2069-79.
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.990        
• Díaz-Alonso J, Paraiso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñóz E. VCE-003.2, a novel cannabigerol derivate, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington´s disease. Sci Rep. 2016 Jul 19;6:29789.
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 5.228        
• Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, Fernández-Ruiz J, García-Arencibia M, Pazos MR. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol Res. 2016 Aug;110:205-15
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.408        
• Palomo-Garo C, Gómez-Gálvez Y, García MC, Fernández-Ruiz J. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacol Res. 2016 Aug;110:181-92
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.408        
• López-Sendón JL, García-Caldentey J, Trigo-Cubillo P, Ruiz-Romero C, García-Ribas G, Alonso-Arias A, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutiérrez S, García-Bermejo ML, Fernández-Ruiz J, Guzmán M, García de Yébenes Prous J. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington´s disease. J Neurol. 2016 Jul;263(7):1390-400
  Categoría: Clinical Neurology       Cuartil: 2º
  Factor de impacto: 3.377        
• Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos MR, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Nagerovic N. Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. J Med Chem. 2016 Jul 28;59(14):6753-71. Mención honorífica. Premios Investigación Fundación Dr. Antonio Esteve.
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 5.589        
• Navarro G, Morales P, Rodríguez-Cueto C, Fernández-Ruiz J, Jagerovic N, Franco R. Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front Neurosci. 2016 Sep 13;10:406
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 3.398        
• Rodríguez-Cueto C, Hernández ML, Hillard C, Maciel P, García-García L, Valdeolivas S, Pozo MA, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3. .Neuroscience. 2016 Dec 17;339:191-209
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 3.231        
• Rubio M, Valdeolivas S, Piscitelli F, Verde R, Satta V, Barroso E, Montolio M, Aras LM, Di Marzo V, Sagredo O, Fernández-Ruiz J. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. Pharmacology Research & Perspectives 4, e00220 (2016)
  Revista pendiente de indexar.        
• Hernández-Folgado L, Stevenson L, Morales P, Gómez-Cañas M, Pazos MR, Cascio MG, Jagerovic N, Elguero J, Pertwee R, Goya P. Exploring the benzimidazole ring as a substitution for indole in cannabinoid allosteric modulators. Cannabis and Cannabinoid Research 1, 196-201 (2016)
  Revista pendiente de indexar.        
• Gómez-Gálvez Y, Palomo-Garo C, Fernández-Ruiz J, García MC. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson´s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:200-8
  Categoría: Clinical Neurology       Cuartil: 1º
  Factor de impacto: 4.025        

2015

• Erdozain A, Rubio M, Valdizán EM, Pazos A, Meana JJ, Fernández-Ruiz J, Alexander S, Callado LF. The endocannabinoid system is altered in the postmortem prefrontal cortex of alcoholic subjects., Addiction Biology, 2015 Jul;20(4):773-83
  Categoría: Substance Abuse       Cuartil: 1º
  Factor de impacto: 5.914        
• Erdozain A, Rubio M, Fernández-Ruiz J, Meana JJ, Callado LF. Altered CB1 receptor coupling to G-proteins in the postmortem caudate nucleus adn cerebellum of alcoholic subjects. Journal of Psychopharmacology 2015 Nov;29(11):1137-45.
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 3.898        
• Ragusa G, Gómez-Cañas M, Morales P, Hurst DP, Deligia F, Pazos MR, Pinna GA, Fernández-Ruiz J, Goya P, Reggio PH, Jagerovic N, García-Arencibia M, Murineddu G. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists. European Journal of Medicinal Chemistry 2015 Jul 15;101:651-667
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 3.432        
• Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to delta-9-tetrahydrocannabinol acting through CB1 receptors. Multiple Sclerosis and Related Disorders 2015 Nov;4(6):505-11
  Categoría: Clinical Neurology       Cuartil: 4º
  Factor de impacto: 0.884        
• Adán de Salas-Quiroga, Javier Díaz-Alonso, Daniel García-Rincón, Floortje Remmers, David Vega, María Gómez-Cañas, Beat Lutz, Manuel Guzmán e Ismael Galve-Roperh. Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13693-8
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 9.674        
• Morales P, Blasco-Benito S, Andradas C, Gómez-Cañas M, Flores J, Goya P, Fernández-Ruiz J, Sánchez C, Jagerovic N. Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple negative breast cáncer. J Med Chem. 2015 Mar 12;58(5):2256-64.
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 5.480        
• Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington´s disease. Neurotherapeutics. 2015 Jan;12(1):185-99
  Categoría: Clinical Neurology       Cuartil: 1º
  Factor de impacto: 3.883        
• García MC, Cinquina V, Palomo-Garo C, Rábano A, Fernández-Ruiz J. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson´s disease. Neurosci Lett. 2015 Feb 5;587:1-4
  Categoría: Neurosciences       Cuartil: 3º
  Factor de impacto: 99.999        
• Espejo-Porras F, Piscitelli F, Verde R, Ramos JA, di Marzo V, de Lago E, Fernández-Ruiz J. Changes in the endocannabinoid signaling sytem in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TPP-43-related disorders. Journal of Neuroimmune Pharmacology 10(2), 233-244 (2015)
  Categoría: Pharmacology & Pharmacy       Cuartil: 2º
  Factor de impacto: 3.172        
• Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C. A Sativex-like combination of phytocannabinoids as disease-modifiying therapy in a viral model of multiple sclerosis. British Journal of Pharmacology 2015 Jul;172(14):3579-95
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.990        
• Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 12, 793-806 (2015)
  Categoría: Clinical Neurology       Cuartil: 1º
  Factor de impacto: 5.054        

2014

• Rodríguez-Cueto C, Benito C, Fernández-Ruiz J, Romero J, Hernández ML, Gómez-Ruiz M. Changes in CB1 and CB2 receptors in the postmortem cerebellum of humans affected by spinocerebellar ataxias. British Journal of Pharmacology 171, 1472-1489 (2014)
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 5.067        
• Fernández-Fernández C, Callado LF, Girón R, Sánchez E, Erdozain AM, López-Moreno JA, Morales P, Rodríguez de Fonseca F, Fernández-Ruiz J, Goya P, Meana JJ, Martín MI, Jagerovic N. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Design, Development & Therapy 8, 263-277 (2014)
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 3.486        
• González-Naranjo P, Pérez N, Campillo NE, Pérez C, Arán VJ, Girón R, Sánchez E, Martín MI, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Páez JA. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer´s disease.European Journal of Medicinal Chemistry 2014;73:56-72.(2014)
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 3.499        
• Endocannabinoid hydrolyzing enzymes in the postmortem cerebellum of humans affected by hereditary autosomal dominat ataxias. Rodríguez-Cueto C, Benito C, Romero J, Hernández ML, Gómez-Ruiz M, Fernández-Ruiz J. Pathobiology;81:149-159 (2014)
  Categoría: Pathology       Cuartil: 3º
  Factor de impacto: 1.948        
• Ooms M, Rietjens R, Rangarajan J, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernández-Ruiz J, Bormans G, Van Laere K, Casteels C. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. Neurobiology of Aging 35, 2858-2869 (2014)
  Categoría: Geriatrics & Gerontology       Cuartil: 1º
  Factor de impacto: 6.166        
• Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, DiMarzo V, Jutras-Aswad D, Notcutt W, Martinez-Orgado J, Robson P, Rohrback B, Thiele E, Whalley B, Friedman D. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014 Jun;55(6):791-802.
  Categoría: Clinical Neurology       Cuartil: 1º
  Factor de impacto: 3.909        
• Chiarlone A, Bellocchio L, Blázquez C, Resel E, Soria-Gómez E, Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sánchez-Prieto J, Lutz B, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proccedings of the National Academy of Sciences of the United States of America 2014 Jun 3;111(22):8257-62
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 9.737        
• Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1G93A transgenic mice and evaluation of a Sativex®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neuroscience & Therapeutics 20, 809-815 (2014)
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 4.443        
• Moreno E, Andradas C, Medrano M, Caffarel MM, Pérez-Gómez E, Blasco-Benito S, Gómez-Cañas M, Pazos MR, Irving AJ, Lluís C, Canela EI, Fernández-Ruiz J, Guzmán M, McCormick PJ, Sánchez C. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. Journal of Biological Chemistry 289, 21960-21972 (2014)
  Categoría: Biochemistry & Molecular Biology       Cuartil: 1º
  Factor de impacto: 4.651

2013

• Alvarado M, Decara J, Luque MJ, Hernández-Folgado L, Gómez-Cañas M, Gómez-Ruiz M, Fernández-Ruiz J, Elguero J, Jagerovic N, Serrano A, Goya P, Rodríguez de Fonseca F. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and LH21. Bioorganic Medicinal Chemistry 21, 1708-1716 (2013)
  Categoría: Chemistry, Organic       Cuartil: 2º
  Factor de impacto: 2.903        
• Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, Gómez-Ruiz M, Callado LF, Goya P, Rodríguez de Fonseca F, Martín MI, Fernández-Ruiz J, Meana JJ, Jagerovic N. Description of a bivalent cannabinoid ligand with hypophagic properties. Arch Pharm (Weinheim). 2013 Mar;346(3):171-9
  Categoría: Chemistry, Multidisciplinary       Cuartil: 2º
  Factor de impacto: 1.540        
• Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti F, Allara M, Sagredo O, di Marzo V, Fernández-Ruiz J. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: potential role of ciclooxygenase-2-dependent metabolism of 2-AG. Celll Death & Disease 4, e862
  Categoría: Cell Biology       Cuartil: 1º
  Factor de impacto: 6.044        
• Morales P, Vara D, Goméz-Cañas M, Zúñiga MC, Olea-Azar C, Goya P, Fernández-Ruiz J, Díaz-Laviada I, Jagerovic N. Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. European Journal of Medicinal Chemistry 70C, 111-119 (2013)
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 3.499        
• Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García MC. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. 2013 Aug 4;75C:155-163
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.114        
• Casarejos MJ, Perucho J, Gómez A, Muñoz MP, Fernández-Estévez M, Sagredo O, Fernández-Ruiz J, Guzmán M, García de Yébenes J, Mena MA. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis. 2013 Jan 1;35(3):525-39
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 4.174        
• Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee RG, Mechoulam R, Martínez-Orgado J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013 Feb;75(2):323-33
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 3.578        
• Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long L, Cravatt B, Giovannoni G, Baker D. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult Scler. 19, 1896-1904
  Categoría: Clinical Neurology       Cuartil: 1º
  Factor de impacto: 4.472        
• Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML. New Serotonin 5-HT1A Receptor Agonists Endowed with Antinociceptive Activity in Vivo. Journal of Medicinal Chemistry, 2013 Oct 24;56(20):7851-61
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 5.614        

2012

• Moreno-Martet M, Mestre L, Loría F, Guaza C, Fernández-Ruiz J, de Lago E. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters 508, 67-72 (2012)
  Categoría: Neurosciences       Cuartil: 3º
  Factor de impacto: 2.026        
• de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández- Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 62, 2299-2308 (2012)
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.114        
• Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DCG, Goya P, Reggio P, Martín MI, Fernández-Ruiz J, Silva AMS, Jagerovic N. Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties. ChemMedChem 7, 452-463 (2012)
  Categoría: Chemistry, Medicinal       Cuartil: 2º
  Factor de impacto: 2.835        
• González-Granja A, Carrillo Salinas F, Pagani A, Gómez-Cañas M, Negui R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Calzado MA, Bellido ML, Fernández-Ruiz J, Appendino G, Guaza C, Muñoz E. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. Journal of Neuroimmune Pharmacology 7, 1002-1016 (2012)
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 3.802        
• Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, Martínez-Orgado J. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 63, 776-783 (2012)
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.114        
• Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington´s disease: Role of CB1 and CB2 receptors. ACS Chem Neurosci. 2012 May 16;3(5):400-6
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 3.871        

2011

• Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental Parkinsonism. Antioxidants & Redox Signaling 14, 2347-2360 (2011).
  Categoría: Endocrinology & Metabolism       Cuartil: 1º
  Factor de impacto: 7.189        
• Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, García de Yébenes J, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. Loss of striatal cannabinoid receptors is a key pathogenic factor in Huntington´s disease. Brain 134, 119-136 (2011).
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 9.915        
• Marco I, Valhondo M, Martín-Fontecha M, Vázquez-Villa H, Del Río J, Planas A, Sagredo O, Ramos JA, Torrecillas IR, Pardo L, Frechilla D, Benhamú B, López-Rodríguez ML. New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage.J Med Chem. 2011 Dec 8;54(23):7986-99.
  Categoría: Chemistry, Medicinal       Cuartil: 1º
  Factor de impacto: 5.614        
• García C, Palomo-Garo C, García-Arencibia M, Ramos JA, Pertwee R, Fernández-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid D9-THCV in animal models of Parkinson´s disease. British Journal of Pharmacology 163, 1495-1506 (2011).
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 5.067        
• Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. Journal of Neurosciences Research 89, 1509-1518 (2011).
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 2.974        
• Rubio M, Villain H, Docagne F, Benoit DR, Ramos JA, Vivien D, Fernández-Ruiz J, Ali C. Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. Plos One 6, e23690 (2011)
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 3.730
• Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Prospects for cannabinoid therapies in basal ganglia disorders. British Journal of Pharmacology 163, 1365-1378 (2011)
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 5.067        

2010

• Fernández-Ruiz, J, Hernandez ML, Ramos JA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neuroscience & Therapeutics 16, 72-91 (2010).
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.443        
• Fernández-Ruiz J, García C, Sagredo O, Gómez M, de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opinion on Therapeutic Targets 14, 387-404 (2010).
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 4.130        
• Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, García-Arencibia M, Nuber S, Schlaudraff F, Liss B, Fernández-Ruiz J, Gerlach M, Wüllner U, Lüddens H, Calabresi P, Auburger G, Gispert S. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.. PLoS One 5, e11464 (2010).
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 3.730        
• Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek, A, Stachurska A, Jozkowicz A, Dulak J, Cuadrado A. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 5, e11838 (2010).
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 3.730        
• Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiology of Disease 37, 434-440 (2010).
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 5.624        
• Sagar D, Jhaveri M, Richardson D, Gray R, de Lago E, Fernández-Ruiz J, Barrett D, Kendall D, Chapman V. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. European Journal of Neuroscience 31, 1414-1422 (2010).
  Categoría: Neurosciences       Cuartil: 2º
  Factor de impacto: 3.753        

2009

• Fernández-Ruiz J. The endocannabinoid system as a target for treatment of motor dysfunction. British Journal of Pharmacology 156, 1029-1040 (2009)
  Categoría: Pharmacology & Pharmacy       Cuartil: 1º
  Factor de impacto: 5.067        
• Arias F, Ampuero I, Sagredo O, Almodovar F, Sánchez S, Gorgojo JJ, Ramos JA. Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study. Psychiatr Genet. 2009 Dec;19(6):336.
  Categoría: Genetics & Heredity       Cuartil: 3º
  Factor de impacto: 2.365        
• Rubio M, de Miguel R, Fernández-Ruiz J, Gutiérrez-López D, Carai MA, Ramos JA. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas. Drug and Alcohol Dependence 99 : 354-358 (2009).
  Categoría: Substance Abuse       Cuartil: 2º
  Factor de impacto: 3.141        
• Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken H, Becker D, Voos W, Leuner K, Müller W, Kudin A, Kunz W, Zimmermann A, Roeper J, Wenzel D, Jendrach M, García-Arencíbia M, Fernández-Ruiz J, Huber L, Rohrer H, Barrera M, Reichert A, Rüb U, Chen A, Nussbaum R, Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLOS One 4, e 5777 (2009)
  Categoría: Multidisciplinary Sciences       Cuartil: 1º
  Factor de impacto: 3.730        
• Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia 57, 1154-1167 (2009)
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 5.066        
• Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 132, 3152-3164 (2009).
  Categoría: Neurosciences       Cuartil: 1º
  Factor de impacto: 9.915        
• Orgado JM, Fernández-Ruiz J, Romero J. The endocannabinoid system in neuropathological states. International Review of Psychiatry 21, 172-180 (2009).
  Categoría: Psychiatry       Cuartil: 2º
  Factor de impacto: 1.798